Rasio utang jangka dawa marang modal Intellia Corp (NTLA)

Intellia Therapeutics (NTLA) is developing cutting-edge treatments through genome editing, yet faces patent conflicts and uncertainty regarding test outcomes. Geopolitical fragmentation and sanctions complicate biomaterial logistics and global research. Meanwhile, the business relies on an autonomous demand cycle, remaining a defensive asset during recessions. The linear price action on the GURU.Markets chart confirms this data, where the indicator stands at 0.07.

This ratio determines the degree of financial leverage by comparing liabilities with a maturity of over one year to equity to assess long-term solvency. The current long-term debt-to-equity ratio is critical for Intellia Therapeutics (NTLA), as the biotech's lack of commercial products and operating losses make it dependent on external borrowings to fund clinical trials.